Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

From vanA Enterococcus hirae tovanA Enterococcus faecium: a Study of Feed Supplementation with Avoparcin and Tylosin in Young Chickens

Beatriz Robredo, Kavindra V. Singh, Fernando Baquero, Barbara E. Murray, Carmen Torres
Beatriz Robredo
Area de Bioquı́mica y Biologı́a Molecular, Universidad de La Rioja, 26004 Logroño, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kavindra V. Singh
Center for the Study of Emerging and Re-emerging Pathogens,
Division of Infectious Diseases, Department of Internal Medicine, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Baquero
Servicio de Microbiologı́a, Hospital Ramón y Cajal, 28034 Madrid, Spain, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara E. Murray
Center for the Study of Emerging and Re-emerging Pathogens,
Division of Infectious Diseases, Department of Internal Medicine, and
Department of Microbiology and Molecular Genetics, The University of Texas Medical School, Houston, Texas 77030
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Torres
Area de Bioquı́mica y Biologı́a Molecular, Universidad de La Rioja, 26004 Logroño, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.43.5.1137
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Fifteen newborn chickens were isolated in separate cages after 1 month of living together, divided into three groups, and challenged for 5 weeks with seed food which either was supplemented with avoparcin (10 mg/kg of animal food) or tylosin (40 mg/kg) or was nonsupplemented. At 9 weeks of age and after the 5-week challenge, all chickens received nonsupplemented feed for 4 additional weeks. At 4, 9, and 13 weeks of life, feces were collected and inoculated on M-Enterococcusagar plates with and without vancomycin (4 μg/ml).vanA-containing Enterococcus hirae was isolated from 11 of 15 chickens before antibiotic challenge, without detection of vancomycin-resistant Enterococcus faecium. At 9 weeks of age and after the 5-week avoparcin challenge, vanA E. hiraestrains were no longer detected, but five of five chickens now hadvanA E. faecium. At a lower frequency, vanA E. faecium had also displaced vanA E. hirae in both the tylosin group (one of four chickens) and the control group (two of five chickens). One month after avoparcin discontinuation, the number of chickens colonized with vanA E. faecium decreased from five to one. All vanA-containing E. hirae strains detected in the first month of life and most of thevanA-containing E. faecium strains detected in the second month of life showed identical ApaI andSmaI restriction patterns, respectively, when analyzed by pulsed-field gel electrophoresis. All vanA E. hiraeisolates transferred glycopeptide and macrolide resistance toEnterococcus faecalis JH2-2 in vitro; the level of glycopeptide resistance was higher in the transconjugants than in the donor E. hirae strains. These data suggest that E. hirae may be a significant source of vanAdeterminants with the potential of transfer to other enterococcal species from humans or animals.

Modern antimicrobial therapy has classified enterococci among the more important nosocomial pathogens. Due to the intrinsic resistance of this genus to several antibiotics, and the increasing prevalence of strains with high-level penicillin (mainly Enterococcus faecium) and aminoglycoside resistance, glycopeptides could be considered as drugs of choice in some severe enterococcal infections. Unfortunately, the emergence of vancomycin resistance (Vanr) over the past few years has become an increasing problem in medical centers throughout the United States and Europe (35). In the United States, the nosocomial prevalence of vancomycin-resistant enterococci (VRE) increased from 0.3 in 1989 to 11 to 13% in non-intensive care unit patients by 1996 (6, 18, 42), and clonal spread of resistant strains has been found (7, 37). The origin of such strains remains controversial. In one study in the United States, VRE (vanA orvanB) were found in stools from 16% of high-risk hospitalized patients, but not from community-based volunteers without hospital exposure, nor from the environment or animals (10). In Europe, VRE are infrequently found among clinical isolates (5, 46, 52), and there is often great heterogeneity among typed isolates (4, 23). Recent studies have consistently found VRE in the environment, including sewage (24, 44), animal samples, and food of animal origin (1, 3, 13, 25, 26, 50). The reported rates of VRE fecal carriage in nonhospitalized Europeans range from 2 to 28% (23, 26, 48, 49). Information about the degree of VRE colonization in carriers and whether this colonization is transient or persistent remains scarce (10, 49). In any case, colonization precedes most infections (15).

The glycopeptide avoparcin has been used as a growth promoter in animal husbandry in Europe (especially in poultry and pigs) since the middle 1970s. An association between the rates of vancomycin resistance in humans and avoparcin usage in animals has been suggested (1, 26, 34, 48). Therefore, the European Union has proposed banning the use of avoparcin as a growth promoter in animals since April 1997. Tylosin is a 16C-macrolide that has also been used for growth promotion. vanA containing Enterococcus strains are frequently resistant to the 14C-macrolide erythromycin. The present study was designed to evaluate the influence of avoparcin and tylosin antibiotics on the selection and evolution of intestinalvanA-containing enterococci in chicken. We also examined the pulsed-field gel electrophoresis (PFGE) patterns of enterococcal isolates collected during the study in order to determine the relatedness between the isolates.

(This study was presented in part at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September to 1 October 1997. [36a].)

MATERIALS AND METHODS

Samples and strain identification.Fifteen newborn chickens were analyzed. One-day-old animals were obtained from a commercial broiler company in Northern Spain and were maintained during the period of the study in a private family-run farm in the same region, which had not used antibiotics as feed supplements. The chicks were maintained in the same cage for 1 month (required for survival), and received non-antibiotic-supplemented seed food. After this month, chickens were separated into newly decontaminated individual cages and individual fecal samples were collected (sample I). Measures were taken to decrease the risk of cross-contamination among cages during the period of the experiment (such as having the cages separated to avoid contact among chickens). Three groups of animals (five animals each) were formed. Group 1 (cages 1C to 5C) animals were maintained with nonsupplemented food, group 2 (cages 1A to 5A) animals were fed with avoparcin-supplemented food (10 mg/kg of animal feed), and group 3 (cages 1T to 5T) animals were fed with tylosin-supplemented food (40 mg/kg). After a time of exposure to the antibiotic-supplemented food of 5 weeks, individual fecal samples were obtained from each chicken (sample II). Antibiotics were then discontinued from the food of all groups. 1 month later, another fecal sample from each chicken was analyzed (sample III). Sample processing was performed as follows. Approximately 1 g of fecal sample was suspended in 3 ml of sterile saline solution and serially 10-fold diluted. A 50-μl aliquot and a 10-μl aliquot of the dilutions were used to inoculate M-Enterococcus agar medium (bioMérieux, Marcy-l’Etoile, France), with and without vancomycin (4 μg/ml), respectively. Plates were incubated at 37°C and examined at 24 and 48 h. Bacterial counts were performed from both the vancomycin-supplemented and nonsupplemented agar plates, and all colonies with the appearance of enterococci that grew on the vancomycin-containing plates were identified by the API 20 Strep system (bioMèrieux), supplemented with biochemical tests as previously recommended (17). To corroborate the identification to the species level, the isolates were tested for the presence of genes coding for E. faecalis antigen A (EfaA) (41), chromosomal E. faecium aminoglycoside acetyltransferase-6′ [AAC(6′)-Ii] (11), and E. hirae muramidase-2 (8), by colony lysis hybridization. Intragenic probes forefaA (730 bp) and aac(6)′-li (323 bp) were generated by PCR from E. faecalis TX4002 and E. faecium TX0016, respectively. The muramidase gene of E. hirae cloned into Escherichia coli pUC19 (9) (kindly provided by Lolita Daneo-Moore) was used as a gene probe forE. hirae. Plasmid DNA was prepared with the Wizard Plus Minipreps kit (Promega, Madison, Wis.) and was digested withEcoRI and EcoRV. These probes were cleaned and labelled with 32P for hybridization (41). Preparation of colony lysates containing denatured enterococcal genomic DNA and hybridizations under high-stringency conditions were carried out by using modified standard protocols (41).

Susceptibility testing.Susceptibility testing was performed with all of the colonies obtained from each vancomycin-containing plate. Only one isolate of a given species per specimen was selected after susceptibility testing, unless a different antibiotic resistance phenotype was observed. MICs of vancomycin (Eli Lilly & Co., Indianapolis, Ind.); avoparcin (Roche, Basel, Switzerland), teicoplanin, and erythromycin (Roussel Uclaf, Paris, France); tylosin, streptomycin, kanamycin, gentamicin, ampicillin, rifampin, and fusidic acid (Sigma Chemical Co., St. Louis, Mo.); and quinupristin-dalfopristin (Rhone-Poulene Rorer, Vitry sur Seine, France) were determined by the agar dilution method according to the National Committee for Clinical Laboratory Standards (36). An Enterococcus isolate for which the MIC of streptomycin or kanamycin was ≥2,000 μg/ml and that of gentamicin was >500 μg/ml was considered as having high-level resistance to these aminoglycosides; borderline results for streptomycin (MIC, 1,000 μg/ml) were tested by using highly charged (300-μg) aminoglycoside disks (38). β-Lactamase was determined by using nitrocefin disks (Becton Dickinson Microbiology Systems, Cockeysville, Md.).

Characterization of resistance genes.PCR was performed, as previously described, to amplify the vanA (53),vanB (9), vanC1 (32), andvanC2 genes (14). As positive controls forvanA, vanB, vanC1, andvanC2 reactions, the strains E. faecium AR1 (44), E. faecium SF299 (19),Enterococcus gallinarum 970, and E. casseliflavus969 (Spanish Culture Type Collection), respectively, were used. Genomic DNA of vancomycin-resistant strains was used for dot-blot hybridization with a vanA probe obtained by PCR (from E. faecium AR1) and labeled with digoxigenin (Boehringer Mannheim DNA labeling and detection kit, Mannheim, Germany). PCR was also performed with high-level gentamicin- and kanamycin-resistantEnterococcus strains to amplify genes coding for the bifunctional AAC(6′)-APH(2") enzyme and the phosphotransferase APH(3′) enzyme, using primers and conditions previously described (47).

Conjugation experiments and plasmid extraction.Transfer of aminoglycosides and vancomycin resistance to the recipient strainsE. faecalis JH2-2 (plasmid free, susceptible to vancomycin and erythromycin, and without high-level resistance to streptomycin and kanamycin, but resistant to rifampin and fusidic acid) (22) and E. faecium GE-1 (susceptible to vancomycin, tylosin, with intrinsic high-level resistance to kanamycin, but not to streptomycin or gentamicin, and resistant to rifampin and fusidic acid) (16) was performed by the filter-mating method. Donor and recipient strains were mixed in a 1:10 ratio. The selective agar plates for transconjugant cells contained vancomycin (4 μg/ml), rifampin (100 μg/ml), and fusidic acid (25 μg/ml). Plasmid DNAs ofvanA-containing Enterococcus isolates and their transconjugants were obtained as previously described, including lysozyme treatment (39).

Bacteriocin activity.Screening for bacteriocin activity was performed by the agar spot test method (45).

PFGE of genomic DNA.All vanA-containing E. hirae and E. faecium strains were analyzed by PFGE. Genomic DNA was prepared in Incert agarose plugs as previously described (43), except for the lysis step, where bacteria in plugs were lysed in EC lysis solution (6 mM Tris, 1 M NaCl, 100 mM EDTA [pH 7.6], 0.5% Brij 58, 0.5% sarcosyl, 0.2% deoxycolic acid, 20 μg of RNase/ml, and 1 mg of lysozyme/ml) for 4 to 6 h only before being treated overnight in ESP solution (0.5 M EDTA [pH 9], 50 μg of proteinase K/ml, and 1% sarcosyl) at 50°C in a shaking water bath. Restriction enzyme ApaI (Gibco BRL, Life Technologies, Gaithersburg, Md.) was used to digest E. hirae DNA in plugs, while SmaI (Gibco BRL) was used to digest E. faecium genomic DNA. One percent I.D.NA agarose (FMC BioProducts Rockland, Maine), prepared in 0.25× TBE (1× TBE is 0.089 M Tris, 0.002 M EDTA, and 0.089 M boric acid) buffer and DNA samples were electrophoresed by using a clamped homogeneous electric field with a CHEF-DR II (Bio-Rad Laboratories, Richmond, Calif.) system with a pulse ramping time from 2 s to 22 s for 16 h. Gels were stained in ethidium bromide and photographed against UV light. Once the isolates having identical patterns were analyzed, a representative isolate of the group was used to compare its restriction pattern with those of the other isolates. Isolates were classified as indistinguishable, closely related, possibly related, or different according to previously published criteria for bacterial strain typing (33).

Statistical analysis.Statistical analyses were performed by geometric means and t test (paired) for comparison of the avoparcin group with the control and tylosin groups by using the statistical program StatView (Abacus Concepts, Berkeley, Calif.).

RESULTS

Identification and PCR results.VRE from chicken fecal samples were identified as E. hirae and E. faecium by the API 20 system supplemented with biochemical tests (17). The DNA probe for aac(6′)-li hybridized under high-stringency conditions only to E. faecium, and the DNA probe for muramidase-2 hybridized only to E. hirae. Negative results were obtained with the E. faecalis probe, efaA. Positive PCR amplification of vanA and negative results forvanB, vanC1, and vanC2 were found in all vancomycin-resistant Enterococcus strains isolated from chicken fecal samples. The DNA probe for vanA hybridized to all VRE isolated from fecal samples.

vanA-containing enterococci in chickens receiving avoparcin-supplemented feed.At the end of the first month of life and immediately before antibiotic challenge, most chickens (11 of 15) harbored vanA-positive E. hirae strains, at concentration of 3.8 × 103 CFU/g of feces (Table1). During the period of intervention, the proportion of chickens in the control group with vanA E. hirae decreased (from three to one), but vanA E. faecium emerged in two chickens, one of which had vanA E. hirae simultaneously with a vanA E. faecium strain. One month after the period of intervention, two of five chickens from the control group harbored vanA E. faecium strains.

View this table:
  • View inline
  • View popup
Table 1.

vanA-containing Enterococcusstrains isolated from 15 chickens during three observation periods

In the avoparcin-challenged group, three of five chickens originally harbored vanA-containing E. hirae; these were replaced after challenge by vanA E. faecium. In the other two chickens, vanA E. faecium was also found after challenge, but was the first vanA isolate. VanA-typeE. faecium strains were found at a mean concentration of 1.1 × 104 CFU/g of feces. Interestingly, vanA E. faecium isolates were not recovered from three of the five animals harboring this resistant organism in the avoparcin group after antibiotic discontinuation. The proportion ofvanA-containing enterococci among the total enterococcal strains was quite variable among animals, but this proportion in the avoparcin-treated group showed a broader range in different animals (range, 0.8 to 45%; mean, 17.9%) than in the control group (range, 0 to 5.5%; mean, 1.6%).

vanA-containing enterococci in chickens receiving tylosin-supplemented feed.All chickens included in the group receiving tylosin-supplemented feed originally harbored vanA E. hirae (five of five). After tylosin challenge, vanA E. hirae disappeared in three chickens, but a vanA E. faecium strain emerged in a single chicken (one of four). One chicken died during this period. Four weeks after tylosin discontinuation, vanA E. faecium was detected in two of four animals (Table 1). The proportion of vanA-containing enterococci among the total enterococcal strains in the tylosin group had a range of 0 to 5% between different animals (mean, 1.2%), similar to that of the control group (mean, 1.6%).

Characteristics of vanA-containing enterococci.In all cases, vanA-containing E. faecium strains showed the following antibiotic susceptibility profile: resistance to vancomycin (MIC, 512 to 1,024 μg/ml), avoparcin (MIC, 64 to 512 μg/ml), teicoplanin (MIC, 128 to 256 μg/ml), erythromycin (MIC, >512 μg/ml), and tylosin (MIC, >256 μg/ml) and absence of high-level resistance to aminoglycosides (streptomycin, gentamicin, and kanamycin) and quinupristin-dalfopristin (Table2). All E. faecium strains were susceptible to ampicillin (MIC, ≤0.5 to 8 μg/ml). Glycopeptide resistance was always transferred by conjugation, and resistance to macrolides was acquired by the recipient strain in 9 of 11 isolates (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

PFGE patterns and MICs of different antibiotics for VanAEnterococcus strains isolated from chicken samples and transconjugants with E. faecalis JH2-2 as the recipient strain

All vanA-containing E. hirae isolates were resistant to vancomycin (MIC, 64 to 128 μg/ml), avoparcin (MIC, 64 to 128 μg/ml), erythromycin (MIC, >512 μg/ml), and tylosin (MIC, >256 μg/ml), but showed lower-level resistance to teicoplanin (MIC, 8 to 32 μg/ml) (Table 2). All of these isolates were highly resistant to streptomycin and kanamycin, and one isolate was also highly resistant to gentamicin (E. hirae B-71). The gene coding for APH(3′) was detected by PCR in these E. hirae isolates, and a positive amplification product (220 bp) was obtained from E. hirae B-71 by PCR with the primers for the aph2"-aac6′gene. All of these isolates were susceptible to quinupristin-dalfopristin. One of 14 E. hirae isolates showed low-level ampicillin resistance (MIC, 16 μg/ml), and no β-lactamase production was detected. Glycopeptide resistance was transferred by conjugation to E. faecalis JH2-2 from all isolates, and transconjugants expressed high-level resistance to both vancomycin (MIC, >256) and teicoplanin (MIC, ≥256), even higher than that in the donor strains. Transfer of vancomycin resistance was always associated with transfer of streptomycin resistance. Resistance to erythromycin and tylosin was also cotransferred with resistance to glycopeptides from 10 of 14 E. hirae isolates; transfer of macrolide resistance was always associated with transfer of kanamycin resistance.

In 11 vanA-containing Enterococcus strains, the plasmid-content was investigated. A high-molecular-weight plasmid was detected in five of six E. hirae isolates and in three of five E. faecium isolates. Transfer of vancomycin resistance was associated with the acquisition of this high-molecular-weight plasmid in three of the E. faecium isolates; in only one case was erythromycin resistance cotransferred. Plasmids were not detectable in vancomycin-resistant transconjugants from E. hirae isolates.

No bacteriocin production by the vanA E. faecium strains could be demonstrated when assayed against the vanA E. hiraestrains of this study.

PFGE.Thirteen E. hirae isolates collected from chicken fecal samples demonstrated identical ApaI restriction patterns when analyzed by PFGE and were assigned the pattern designation Ehi-A (Fig.1). One isolate differed by three bands from the other 13 isolates and was characterized as a variant of the Ehi-A pattern (Fig. 1). Analysis of 13 E. faecium isolates by SmaI digestion revealed four different PFGE patterns (Fig. 2). Eight isolates of E. faecium showed identical SmaI restriction patterns and were designated as the Efm-A pattern. The pattern designation Efm-C was assigned to twoE. faecium strains with identical PFGE patterns. A thirdE. faecium strain showed a closely related (single-band difference) PFGE pattern, Efm-C1. Two other E. faecium strains showed PFGE patterns completely different from each other and from the other isolates and were designated as Efm-D and Efm-B, respectively (Fig. 2).

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

PFGE of ApaI-digested genomic DNA fromvanA-containing E. hirae strains. Lanes: 1, Efm-A1 pattern; 2, Efm-A pattern.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

PFGE of SmaI-digested genomic DNA fromvanA-containing E. faecium strains. Lanes: 1, Efm-A pattern; 2, Efm-C pattern; 3, Efm-C1 pattern; 4, Efm-D pattern; 5, Efm-B pattern.

DISCUSSION

E. hirae isolates containing vanA were consistently detected in the feces of newborn chickens fed with nonsupplemented seeds. The origin of the resistant strains may be the broiler company. The seed may be contaminated withEnterococcus (20), but we were unable to detectvanA-containing enterococci when seed preparations were inoculated on selective culture media containing vancomycin (data not shown). The presence of a common strain of vanA-containingE. hirae in most animals under observation likely relates to the common occupancy of a single cage by all chickens during the initial period of the experiment. Isolation is impossible at very early stages of chicken growth, because it is followed by high spontaneous mortality. The proportion of vanA-containing E. hirae strains in the total number of Enterococcusstrains was variable among animals, suggesting that some were more likely to serve as a source for cross-contamination. Similar spread would be expected to occur under normal circumstances in chicken farms. In both antibiotic-supplemented and nonsupplemented animals, vanA E. hirae tended to disappear during the second month of life, confirming its role as a member of the early bacterial community in the chicken gut, as has been previously shown with vancomycin-susceptibleE. hirae strains (12). Nevertheless, at this stage, the vanA determinant was now detectable in E. faecium. It is possible that the original population of E. hirae strains may have been naturally replaced by a formerly minority vanA E. faecium subpopulation undetected in previous samples. On the other hand, the possibility of in vivo transfer of vanA from E. hirae to E. faecium can also be considered. Such transfer occurs under in vitro conditions; moreover, in at least one animal, both vanA E. hirae and vanA E. faecium strains were simultaneously present in the intestine. Specific replacement due to bacteriocin production was not suggested by the results of in vitro competition assays.

The addition of avoparcin to the food was associated with the appearance of vanA-containing E. faecium strains in all challenged animals; discontinuation of the antibiotic for 1 month was followed by the failure to detect these isolates in four of the five chickens. The differences in numbers of chickens colonized and the number of VRE were not statistically significantly different, perhaps because of the small number of chickens studied and the low concentration of avoparcin feed. The average cell density of VRE in feces from avoparcin-treated chickens was about 11 times higher than that in nontreated animals. These data suggest that avoparcin had some selective effect and that, in the absence of selection, vancomycin-susceptible enterococci present in the intestinal content may overgrow the resistant organisms. In some animals, colonization by resistant enterococci may last much longer; Bager et al. (2) detected vancomycin (vanA)-resistant strains 6 months after discontinuation of avoparcin feeding in pigs and poultry.

Tylosin supplementation did not appear to select forvanA-containing strains, despite the fact that all vancomycin-resistant strains were tylosin resistant. The use of other growth promoters in animals, tylosin in this case and virginiamycin in the report of Welton et al. (51), did not appear to select for vanA-containing enterococci.

All vanA E. hirae strains detected in the first month of the chickens’ lives in the control, avoparcin, and tylosin groups showed identical ApaI restriction patterns when analyzed by PFGE (pattern Ehi-A). In the second month, when addition of avoparcin and tylosin started, vanA E. hirae strains tended to disappear and to be replaced by vanA E. faecium. AllvanA E. faecium isolates recovered in the second month showed identical SmaI patterns (pattern Efm-A), except for two strains detected in the avoparcin group that showed a completely different pattern (Efm-C and its closely related Efm-C1 pattern). However, after discontinuation of the antibiotic for 1 month, three different vanA E. faeciumpatterns were found in the avoparcin and tylosin groups, while in the control group, the vanA E. faecium population, pattern Efm-A was the only one detected. The variability of the patterns detected in the avoparcin and tylosin groups and the continuity in control group suggest that avoparcin and tylosin may have contributed to expansion of the vanA E. faecium population.

The vanA-containing E. hirae strains expressed a lower level of glycopeptide resistance than E. faecium. This phenomenon occurred both with vancomycin (mode MIC, 64 to 128 versus 512 to 1,024 μg/ml, respectively) and teicoplanin (mode MIC, 8 to 32 versus 128 to 256 μg/ml). The glycopeptide MICs of the recipientE. faecalis strains after conjugation with E. hirae were in the E. faecium range, suggesting that the same vanA gene cluster may have a lower level of expression in E. hirae than in E. faecalis or E. faecium. The vancomycin resistance gene cluster may have different levels of expression in different species (21, 29).

Different patterns of cotransfer of macrolide resistance and glycopeptide resistance were found by using E. hirae strains as donors, despite the fact that all of the E. hiraeisolates showed a common PFGE pattern. In 10 of 14 instances, E. faecalis transconjugants with both macrolide and glycopeptide resistance were recovered, but in 4 of these 10, there were also transconjugants in which only glycopeptide resistance was transferred.E. faecalis transconjugants were obtained with both macrolide and glycopeptide resistance from 9 of 11 E. faecium donors, but in 1 of 9 of these strains, transconjugants also were derived that showed only vancomycin resistance; 2 of 11 had only macrolide resistance. These results suggest that both resistances are in separate replicons that are frequently cotransferred.

One of the vanA E. hirae strains showed high-level gentamicin resistance, and the gene coding for the bifunctional AAC(6′)-APH(2") enzyme was detected by PCR. This strain showed the sameApaI restriction pattern as the others that were gentamicin susceptible, which suggests that the gene encoding the bifunctional AAC(6′)-APH(2") may have been located in a plasmid and transferred in vivo. McNamara et al. (31) found high-level gentamicin resistance in 34% of E. hirae clinical isolates, and the genetic determinant for the bifunctional enzyme in this species was shown to be homologous to that characterized in other species, such asE. faecalis and E. faecium (29).

vanA E. hirae strains have been previously isolated from water (27) and humans (40). The incidence of this species in the human flora has probably been underestimated, but may account for 3% of enterococcal clinical isolates (31). The rate of acquisition of vancomycin-resistant E. hirae strains of chicken origin by human populations and its role as a source of vancomycin and macrolide resistance determinants remain to be evaluated.

These results suggest that vancomycin resistance may be common in newborn chickens in Northern Spain, and the epidemiology of vanA E. hirae strains may be of interest, because this species may well be a reservoir for glycopeptide resistance. Despite the low number of chickens studied, our data indicate that avoparcin supplementation may increase the selection of glycopeptide-resistant enterococci, but this effect may be transient. Tylosin was not associated with glycopeptide selection, suggesting that the selective measure was mainly exerted on the non-vanA-containing Enterococcus populations. Because the acquisition of tylosin resistance implies cross-resistance with all macrolide antibiotics, and avoparcin resistance correlates with vancomycin and teicoplanin resistance, a closer surveillance of the chicken reservoir of antibiotic-resistant Enterococcusshould be urgently considered.

ACKNOWLEDGMENTS

This work was supported by a grant from the Ministerio de Salud y Consumo of Spain (FIS 98/0282).

We thank Carmen Robledo for helping us care for the chickens, Emilia Cercenado for providing E. faecium SF299, and Teresa Coque for critical review of the manuscript.

FOOTNOTES

    • Received 21 September 1998.
    • Returned for modification 11 January 1999.
    • Accepted 5 March 1999.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Aarestrup F. M.
    Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. Microb. Drug Res. 1 1995 255 257
    OpenUrl
  2. 2.↵
    1. Bager F.,
    2. Madsen M.,
    3. Christensen J.,
    4. Aarestrup F. M.
    Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms. Prev. Vet. Med. 31 1997 95 112
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Bates E. M.,
    2. Jordens J. Z.,
    3. Griffiths D. T.
    Farm animals as a putative reservoir for vancomycin resistant enterococcal infections in man. J. Antimicrob. Chemother. 34 1994 507 516
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Bingen E. H.,
    2. Denamur E.,
    3. Lambert-Zechovsky N. Y.,
    4. Elion J.
    Evidence for the genetic unrelatedness of nosocomial vancomycin-resistant Enterococcus faecium strains in a pediatric hospital. J. Clin. Microbiol. 29 1991 1888 1892
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Brown D. F. J.,
    2. Courvalin P.,
    3. the European Glycopeptide Resistance Group
    European glycopeptide susceptibility survey: susceptibility of Enterococcus spp to teicoplanin and vancomycin, abstr. E26 Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996 85 American Society for Microbiology Washington, D.C
  6. 6.↵
    Centers for Disease Control and Prevention Nosocomial enterococci resistant to vancomycin—United States, 1989–1993. Morbid. Mortal. Weekly Rep. 42 1993 597 599
    OpenUrlPubMed
  7. 7.↵
    1. Chow J. W.,
    2. Kuritza A.,
    3. Shlaes D. M.,
    4. Green M.,
    5. Sahm D. F.,
    6. Zervos M. J.
    Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J. Clin. Microbiol. 31 1993 1609 1611
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Chu C.-P.,
    2. Kariyama R.,
    3. Daneo-Moore L.,
    4. Shockman G. D.
    Cloning and sequence analysis of the muramidase-2 gene from Enterococcus hirae. J. Bacteriol. 174 1992 1619 1625
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Clark N. C.,
    2. Cooksey R. C.,
    3. Hill B. C.,
    4. Swenson J. M. S.,
    5. Tenover F. C.
    Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob. Agents Chemother. 37 1993 2311 2317
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Coque T. M.,
    2. Tomayko J. F.,
    3. Ricke S. C.,
    4. Okhyusen P. C.,
    5. Murray B. E.
    Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob. Agents Chemother. 40 1996 2605 2609
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Costa Y.,
    2. Galimand M.,
    3. Leclercq R.,
    4. Duval J.,
    5. Courvalin P.
    Characterization of the chromosomal aac(6′)-Ii gene specific for Enterococcus faecium. Antimicrob. Agents Chemother. 37 1993 1896 1903
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Devriese L. A.,
    2. Hommez J.,
    3. Wijfels R.,
    4. Haesebrouck F.
    Composition of the enterococcal and streptococcal intestinal flora of poultry. J. Appl. Bacteriol. 71 1991 46 50
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Devriese L. A.,
    2. Ieven M.,
    3. Goossens H.,
    4. Vandamme P.,
    5. Pot B.,
    6. Hommez J.,
    7. Haesebrouck F.
    Presence of vancomycin-resistant enterococci in farm and pet animals. Antimicrob. Agents Chemother. 40 1996 2285 2287
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Dutka-Malen S.,
    2. Evers S.,
    3. Courvalin P.
    Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33 1995 24 27
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Edmond M. B.,
    2. Ober J. F.,
    3. Weinbaum D. L.,
    4. Pfaller M. A.,
    5. Hwang T.,
    6. Sanford M. D.,
    7. Wenzel R. Y.
    Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis. 20 1995 1126 1133
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Eliopoulos G. M.,
    2. Wennersten C.,
    3. Zighelboim-Daum S.,
    4. Goldmann D.,
    5. Moellering R. C. Jr.
    High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob. Agents Chemother. 32 1988 1528 1532
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Facklam R. R.,
    2. Collins M. D.
    Identification of Enterococcus species isolated from human infections by a conventional test scheme. J. Clin. Microbiol. 27 1989 731 734
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Gaynes R.,
    2. Edwards J.
    National Nosocomial Infection Surveillance (NNIS) System. Nosocomial vancomycin resistant enterococci (VRE) in the United States, 1989–1995: the first 1000 isolates. Infect. Control Hosp. Epidemiol. 17 (Suppl.) 1996 P18
    OpenUrl
  19. 19.↵
    1. Gold H. S.,
    2. Cercenado E.,
    3. Thauvin-Eliopoulos C.,
    4. Eliopoulos G. M.,
    5. Wennerstern C. B.,
    6. Moellering R. C. Jr.
    A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB,vanA, and vanC genes of enterococci. Antimicrob. Agents Chemother. 37 1993 1604 1609
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Guillot J. F.,
    2. Chaslus-Dancla E.,
    3. Lafont J. P.
    Spontaneous implantation of antibiotic-resistant Enterobacteriaceae in the digestive tract of chickens in the absence of selective pressure. Antimicrob. Agents Chemother. 12 1977 697 702
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Hayden M. K.,
    2. Picken R. N.,
    3. Sahm D. F.
    Heterogeneous expression of glycopeptide resistance in enterococci associated with transfer of vanB. Antimicrob. Agents Chemother. 41 1997 872 874
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Jacob A. E.,
    2. Hobbs S. J.
    Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes. J. Bacteriol. 117 1974 360 372
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Jordens J. Z.,
    2. Bates J.,
    3. Griffiths D. T.
    Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. J. Antimicrob. Chemother. 34 1994 515 528
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Klare I.,
    2. Heier H.,
    3. Claus H.,
    4. Witte W.
    Environmental strains of Enterococcus faecium with inducible high-level resistance to glycopeptides. FEMS Microbiol. Lett. 106 1993 23 30
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Klare I.,
    2. Heier H.,
    3. Claus H.,
    4. Reissbrodt R.,
    5. Witte W.
    vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol. Lett. 125 1995 165 172
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Klare I.,
    2. Heier H.,
    3. Claus H.,
    4. Reissbrodt R.,
    5. Witte W.
    Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community. Microb. Drug Res. 1 1995 265 272
    OpenUrlCrossRef
  27. 27.↵
    1. Knudtson J. M.,
    2. Hartman P. A.
    Antibiotic resistance among enterococcal isolates from environmental and clinical sources. J. Food Prot. 56 1993 489 492
    OpenUrlWeb of Science
  28. 28.
    1. Leclercq R.,
    2. Derlot E.,
    3. Duval J.,
    4. Courvalin P.
    Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319 1988 157 161
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Leclercq R.,
    2. Derlot E.,
    3. Weber M.,
    4. Duval J.,
    5. Courvalin P.
    Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 33 1989 10 15
    OpenUrlAbstract/FREE Full Text
  30. 30.
    1. Mangan M. W.,
    2. McNamara E. B.,
    3. Smyth E. G.,
    4. Storrs M. J.
    Molecular genetic analysis of high-level gentamicin resistance in Enterococcus hirae. J. Antimicrob. Chemother. 40 1997 377 382
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. McNamara E. B.,
    2. King E. M.,
    3. Smyth E. G.
    A survey of antimicrobial susceptibility of clinical isolates of Enterococcus spp. from Irish hospitals. J. Antimicrob. Chemother. 35 1995 185 189
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Miele A.,
    2. Bandera M.,
    3. Goldstein B. P.
    Use of primers selective for vancomycin resistance genes to determine van genotype in enterococci and to study gene organization in vanA isolates. Antimicrob. Agents Chemother. 39 1995 1772 1778
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Murray B. E.,
    2. Singh K. V.,
    3. Markowitz S. M.,
    4. Lopardo H. A.,
    5. Patterson J. E.,
    6. Zervos M. J.,
    7. Rubeglio E.,
    8. Eliopoulos G. M.,
    9. Rice L. B.,
    10. Goldstain F. W.,
    11. Jenkins S. G.,
    12. Caputo G. M.,
    13. Nasnas R.,
    14. Moore L. S.,
    15. Wong E. S.,
    16. Weinstock G.
    Evidence for clonal spread of a single strain of β-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J. Infect. Dis. 163 1991 780 785
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Murray B. E.
    What can we do about vancomycin resistant enterococci? Clin. Infect. Dis. 20 1995 1134 1136
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Murray B. E.
    Vancomycin-resistant enterococci. Am. J. Med. 102 1997 284 293
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility testing on bacteria that grow aerobically 4th ed. Approved standard M7-A4. 1997 National Committee for Clinical Laboratory Standards Wayne, Pa
  37. 36a.↵
    1. Robredo B.,
    2. Torres C.,
    3. Ruiz F.,
    4. Baquero F.
    Evolution of vanA Enterococcus populations in faeces of newborn chickens receiving avoparcin and tylosin as food additives, abstr. C-132 Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 69 American Society for Microbiology Washington, D.C
  38. 37.↵
    1. Sader H. S.,
    2. Pfaller M. A.,
    3. Tenover F. C.,
    4. Hollis R. J.,
    5. Jones R. N.
    Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers. J. Clin. Microbiol. 32 1994 2840 2842
    OpenUrlAbstract/FREE Full Text
  39. 38.↵
    1. Sahm D. F.,
    2. Torres C.
    High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis. J. Clin. Microbiol. 26 1988 257 260
    OpenUrlAbstract/FREE Full Text
  40. 39.↵
    1. Sambrook J.,
    2. Fritsch E. F.,
    3. Maniatis T.
    Molecular cloning: a laboratory manual 2nd ed. 1989 1.25 1.27 Cold Spring Harbor Laboratory Press Cold Spring Harbor, N.Y
  41. 40.↵
    1. Simonsen G. S.,
    2. Haaheim H.,
    3. Kruse H.,
    4. Dahl K. H.,
    5. Olsvik Ø.,
    6. Sundsfjord A.
    The possible horizontal transmission of the vanA gene cluster between chicken and human GRE-strains at avoparcin-exposed farms, abstr. C-131 Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997 69 American Society for Microbiology Washington, D.C
  42. 41.↵
    Singh, K. V., T. M. Coque, G. M. Weinstock, and B. E. Murray. In vivo testing of anEnterococcus faecalis efaA mutant and use of efaAhomologs for species identification. FEMS Immunol. Med. Microbiol.21:323–331.
  43. 42.↵
    1. Tenover F. C.,
    2. Gaynes R.
    Dissemination of vancomycin-resistant enterococci in the United States Bacterial resistance to glycopeptides. Brun-Buisson C., Eliopoulos G. M., Leclercq R. 1998 102 110 Medicine Sciences Flammarion Paris, France
  44. 43.↵
    1. Tenover F. C.,
    2. Arbeit R. D.,
    3. Goering R. V.,
    4. Mickelsen P. A.,
    5. Murray B. E.,
    6. Persing D. H.,
    7. Swaminathan B.
    Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33 1995 2233 2239
    OpenUrlFREE Full Text
  45. 44.↵
    1. Torres C.,
    2. Reguera J. A.,
    3. SanMartin M. J.,
    4. Pérez-Dı́az J. C.,
    5. Baquero F.
    vanA-mediated vancomycin-resistant Enterococcus spp. isolated from sewage. J. Antimicrob. Chemother. 33 1994 553 561
    OpenUrlCrossRefPubMedWeb of Science
  46. 45.↵
    1. Uhlman L.,
    2. Schillinger U.,
    3. Rupnow J. R.,
    4. Holzapfel W. H.
    Identification and characterization of two bacteriocin-producing strains of Lactococcus lactis isolated from vegetables. Int. J. Food Microbiol. 16 1992 141 151
    OpenUrlCrossRefPubMedWeb of Science
  47. 46.↵
    1. Vandamme P.,
    2. Vercauteren E.,
    3. Lammens C.,
    4. Pensart N.,
    5. Ieven M.,
    6. Pot B.,
    7. Leclercq R.,
    8. Goossens H.
    Survey of enterococcal susceptibility patterns in Belgium. J. Clin. Microbiol. 34 1996 2572 2576
    OpenUrlAbstract/FREE Full Text
  48. 47.↵
    1. van de Klundert J. A. M.,
    2. Vliegenthart J. S.
    PCR detection of genes coding for aminoglycoside-modifying enzymes Diagnostic molecular microbiology. Principles and applications. Persing D. H., Smith T. F., Tenover F. C., White T. J. 1993 547 552 American Society for Microbiology Washington, D.C
  49. 48.↵
    1. Van den Bogaard A. E.,
    2. Stobbergingh E. E.
    Time to ban all antibiotics as animal growth-promoting agents? Lancet 348 1996 619
    OpenUrlPubMed
  50. 49.↵
    1. Van der Auwera P.,
    2. Pensart N.,
    3. Korten V.,
    4. Murray B. E.,
    5. Leclercq R.
    Incidence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide resistant enterococci. J. Infect. Dis. 173 1996 1129 1136
    OpenUrlCrossRefPubMedWeb of Science
  51. 50.↵
    1. Wegener H. C.,
    2. Madsen M.,
    3. Nielsen N.,
    4. Aarestrup F. M.
    Isolation of vancomycin resistant Enterococcus faecium from food. Int. J. Food Microbiol. 35 1997 57 66
    OpenUrlCrossRefPubMedWeb of Science
  52. 51.↵
    1. Welton L. A.,
    2. Thal L. A.,
    3. Perry M. B.,
    4. Donabedian S.,
    5. McMahon J.,
    6. Chow J. W.,
    7. Zervos M. J.
    Antimicrobial resistance in enterococci isolated from turkey flocks fed virginiamycin. Antimicrob. Agents Chemother. 42 1998 705 708
    OpenUrlAbstract/FREE Full Text
  53. 52.↵
    1. Witte W.,
    2. Klare I.
    Glycopeptide resistant Enterococcus faecium outside hospitals: a commentary. Microb. Drugs Res. 3 1995 259 263
    OpenUrl
  54. 53.↵
    1. Woodford N.,
    2. Morrison D.,
    3. Johnson A. P.,
    4. Briant V.,
    5. George R. C.,
    6. Cookson B.
    Application of DNA probes for rRNA and vanA genes to investigation of a nosocomial cluster of vancomycin-resistant enterococci. J. Clin. Microbiol. 31 1993 653 658
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
From vanA Enterococcus hirae tovanA Enterococcus faecium: a Study of Feed Supplementation with Avoparcin and Tylosin in Young Chickens
Beatriz Robredo, Kavindra V. Singh, Fernando Baquero, Barbara E. Murray, Carmen Torres
Antimicrobial Agents and Chemotherapy May 1999, 43 (5) 1137-1143; DOI: 10.1128/AAC.43.5.1137

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
From vanA Enterococcus hirae tovanA Enterococcus faecium: a Study of Feed Supplementation with Avoparcin and Tylosin in Young Chickens
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
From vanA Enterococcus hirae tovanA Enterococcus faecium: a Study of Feed Supplementation with Avoparcin and Tylosin in Young Chickens
Beatriz Robredo, Kavindra V. Singh, Fernando Baquero, Barbara E. Murray, Carmen Torres
Antimicrobial Agents and Chemotherapy May 1999, 43 (5) 1137-1143; DOI: 10.1128/AAC.43.5.1137
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Bacterial Proteins
Carbon-Oxygen Ligases
Drug Resistance, Microbial
Enterococcus
glycopeptides
Tylosin

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596